30 closest matches · ranked by relevance
Asthma
Primary: Baseline-adjusted Area Under the Serial FEV1-time Curve Calculated From Time Zero to 12 Hours (AUC0-12h) on Day 1 of Treatment — 4.03; 3.96 liters x hours
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Mean Difference in Intraocular Pressure of Both Eyes Between the Two Treatment Groups — 24.92; 25.06; 24.87; 25.12 mmHg
Tinea Pedis
Primary: Proportion of Patients in Each Active Treatment Group Who Are Considered a Therapeutic Cure — 96; 81 Participants
Obstructive Sleep Apnea
Primary: Apnea/Hypopnea Index — 2.9; 3.2 events/h
Metastatic Breast Cancer
Primary: Objective Response Rate — 138; 143 Participants
Epilepsy
Primary: AUC — 101346; 101393 ng*hr/ml
Healthy
Primary: Baseline Corrected Maximum Observed Plasma Concentration (Cmax[Adj]) of Levothyroxine Sodium — 67.258; 60.552 Nanogram per milliliter (ng/mL)
Actinic Keratosis
Primary: Number of Participants With 100% Clearance of Actinic Keratosis Lesions: Comparison of Taro Imiquimod 5% and Aldara-Imiquimod 5% — 63; 54 Participants
Healthy Adults
Primary: Mean Plasma Concentration (AUC) of Cyclobenzaprine — 70066.90; 64711.53 pg*h/mL
Bronchial Asthma
Primary: Change in FEV1 From Pre Dose to End of Treatment — 0.23; 0.22; 0.09 Litres
Healthy
Primary: Letrozole : AUC0-tz — 2074.71; 2094.63 ng•hr/mL
Actinic Keratoses
Primary: Percentage of Subjects in Each Treatment Group With Complete Clearance of AK Lesions at the Test of Cure Visit (Week 24) — 74; 72; 7 Participants — p=0.0001
ACTINIC KERATOSIS
Primary: Complete Clearance of AK Lesions — 45; 44; 7 Participants
Glaucoma · Open Angle or Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Week 12 — 20.6; 20.8 mmHg
Atrophic Vaginitis
Primary: Number of Participants Identified as a Responder After Completing Study Treatment in the Generic Estradiol Vaginal Cream and Estrace Vaginal Cream Groups — 49; 44…
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Tepotinib — 15348; 16523 Hours*nanogram per milliliter…
Vulvovaginal Candidiasis
Primary: Proportion of Subjects in Each Treatment Group With Therapeutic Cure — 105; 93 participants
Head Lice
Primary: Number of Participants With Infestation Successfully Eliminated by Active Treatment. — 59; 57; 6 Participants
Metastatic Breast Cancer
Primary: Area Under the Concentration Time Curve at Steady State (AUCss) — 34400; 31800 ug*h/mL
HIV/AIDS
Primary: Area Under the Concentration-Time Curve(AUC) — 3.6; 3.4; 85.8; 79.2 hour*milligram/liter
Glaucoma · Open Angle or Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 20.07; 19.89 mmHg
Bioequivalence
Primary: Concentration Maximum (Cmax) — 0.9092; 0.8711 ng/ml
Hereditary Tyrosinemia, Type I
Primary: Maximum Observed Plasma Concentration (Cmax) — 1277.77; 1272.34; 1339.79 ng/mL
Smoking Cessation
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Time t [AUC(0-t)] — 18.84; 20.71; 34.71; 33.68 nanogram (ng).hour (hr)/millilitre (mL)
Osteoarthritis, Knee
Primary: Mean Change From Baseline to Week 8 in WOMAC Pain Scale, Bioequivalence of Test to Reference. — 6.8; 6.7; 5.9 units on a scale
Healthy
Primary: Part A: Area Under the Concentration-time Curve of Alteplase in Plasma Over the Time Interval From 0 up to the Last Quantifiable Data Point (AUC0-tz)
Dermatitis, Contact
Primary: Analysis of Bioequivalence: Concordance — 76; 98.0 percentage of agreement
Healthy
Primary: Area Under the Concentration-Time Curve From Zero Time Until the Last Sampling Time (AUCt) — 126.36; 129.48; 122.33; 119.75 ng*h/mL
Scabies
Primary: Number of Patients in Each Treatment Group With Therapeutic Cure (Parasitological Cure Plus Clinical Cure) of Scabies — 83; 86 Participants
Vulvar and Vaginal Atrophy
Primary: The Primary Efficacy Endpoint — 49; 59; 52; 63 participants — p=<0.0001